Ekaterina Yakovleva, Mekhriniso Kamalova, Mariia Brusina, Evgenii Bychkov, L. Piotrovskiy, Petr Shabanov
{"title":"研究 nmda 受体复合物新配体的镇痛活性","authors":"Ekaterina Yakovleva, Mekhriniso Kamalova, Mariia Brusina, Evgenii Bychkov, L. Piotrovskiy, Petr Shabanov","doi":"10.17816/rcf624859","DOIUrl":null,"url":null,"abstract":"According to the Russian Society for the Study of Pain, 90% of patients seeking medical help experience pain, with 70% suffering from chronic pain [15, 16]. It should be acknowledged that the capabilities of traditional analgesic methods are limited, and the prescription of opioids is associated with an increase in complications, the development of tolerance, drug dependence, and an increase in the patient's hospital stay costs. Thus, the main directions for improving pain relief include the rational combination of analgesics with different mechanisms of action and the development of new effective and safe medicinal substances with analgesic activity. It is known that the activation of spinal cord NMDA receptors is a key factor in the pathogenesis of acute and chronic pain. Therefore, the use of existing NMDA antagonists in analgesic schemes, as well as the development of new compounds targeting the NMDA receptor complex, is of particular interest. New ligands of the glutamate NMDA receptor complex are derivatives of imidazole-4,5-dicarboxylic acid. The conformational rigidity of the molecules of imidazole-4,5-dicarboxylic acid derivatives allow for increased selectivity of interaction and reduced side effects. The aim of the study was to investigate the analgesic effect of new ligands of the glutamate NMDA receptor complex - derivatives of imidazole-4,5-dicarboxylic acid in mice using the tail-flick test and the formalin test. The tested compounds (IEM-303 and IEM-2044) were administered intraperitoneally at doses of 5, 10, 15, 20 mg/kg. Мetamizole was used as a comparison drug. The experiments demonstrated a significant dose-dependent analgesic effect of the tested compounds in experimental models of acute pain at doses of 5-20 mg/kg. In the groups receiving IEM-2044 and IEM-303, the tail-flick latency increased by 1.4-1.7 times compared to the control group. The analgesic activity of the tested compounds at doses of 10-20 mg/kg was comparable to the analgesic activity of metamizole, indicating the prospect of developing these agents and further searching for effective and safe analgesics among this pharmacological class.","PeriodicalId":21186,"journal":{"name":"Reviews on Clinical Pharmacology and Drug Therapy","volume":"4 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"INVESTIGATION OF THE ANALGESIC ACTIVITY OF NEW LIGANDS OF THE NMDA RECEPTOR COMPLEX\",\"authors\":\"Ekaterina Yakovleva, Mekhriniso Kamalova, Mariia Brusina, Evgenii Bychkov, L. Piotrovskiy, Petr Shabanov\",\"doi\":\"10.17816/rcf624859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"According to the Russian Society for the Study of Pain, 90% of patients seeking medical help experience pain, with 70% suffering from chronic pain [15, 16]. It should be acknowledged that the capabilities of traditional analgesic methods are limited, and the prescription of opioids is associated with an increase in complications, the development of tolerance, drug dependence, and an increase in the patient's hospital stay costs. Thus, the main directions for improving pain relief include the rational combination of analgesics with different mechanisms of action and the development of new effective and safe medicinal substances with analgesic activity. It is known that the activation of spinal cord NMDA receptors is a key factor in the pathogenesis of acute and chronic pain. Therefore, the use of existing NMDA antagonists in analgesic schemes, as well as the development of new compounds targeting the NMDA receptor complex, is of particular interest. New ligands of the glutamate NMDA receptor complex are derivatives of imidazole-4,5-dicarboxylic acid. The conformational rigidity of the molecules of imidazole-4,5-dicarboxylic acid derivatives allow for increased selectivity of interaction and reduced side effects. The aim of the study was to investigate the analgesic effect of new ligands of the glutamate NMDA receptor complex - derivatives of imidazole-4,5-dicarboxylic acid in mice using the tail-flick test and the formalin test. The tested compounds (IEM-303 and IEM-2044) were administered intraperitoneally at doses of 5, 10, 15, 20 mg/kg. Мetamizole was used as a comparison drug. The experiments demonstrated a significant dose-dependent analgesic effect of the tested compounds in experimental models of acute pain at doses of 5-20 mg/kg. In the groups receiving IEM-2044 and IEM-303, the tail-flick latency increased by 1.4-1.7 times compared to the control group. The analgesic activity of the tested compounds at doses of 10-20 mg/kg was comparable to the analgesic activity of metamizole, indicating the prospect of developing these agents and further searching for effective and safe analgesics among this pharmacological class.\",\"PeriodicalId\":21186,\"journal\":{\"name\":\"Reviews on Clinical Pharmacology and Drug Therapy\",\"volume\":\"4 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews on Clinical Pharmacology and Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17816/rcf624859\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on Clinical Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/rcf624859","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
根据俄罗斯疼痛研究学会(Russian Society for the Study of Pain)的数据,90%的求医者都经历过疼痛,其中 70% 为慢性疼痛[15, 16]。应该承认,传统镇痛方法的能力是有限的,而且阿片类药物的处方与并发症的增加、耐受性的产生、药物依赖性以及患者住院费用的增加有关。因此,改善镇痛效果的主要方向包括合理组合具有不同作用机制的镇痛药,以及开发有效、安全且具有镇痛活性的新药物。众所周知,脊髓 NMDA 受体的激活是急性和慢性疼痛发病机制的关键因素。因此,在镇痛方案中使用现有的 NMDA 拮抗剂以及开发以 NMDA 受体复合物为靶点的新化合物尤其令人感兴趣。谷氨酸 NMDA 受体复合物的新配体是咪唑-4,5-二羧酸的衍生物。咪唑-4,5-二羧酸衍生物分子的构象刚度可提高相互作用的选择性并减少副作用。研究的目的是通过尾搔试验和福尔马林试验,研究谷氨酸 NMDA 受体复合物的新配体--咪唑-4,5-二羧酸衍生物对小鼠的镇痛效果。受试化合物(IEM-303 和 IEM-2044)的腹腔给药剂量分别为 5、10、15 和 20 毫克/千克。Мetamizole 用作对比药物。实验表明,在急性疼痛实验模型中,剂量为 5-20 毫克/千克的受试化合物具有显著的剂量依赖性镇痛效果。与对照组相比,接受 IEM-2044 和 IEM-303 治疗组的尾搔潜伏期延长了 1.4-1.7 倍。在剂量为 10-20 毫克/千克时,受试化合物的镇痛活性与甲氰咪唑的镇痛活性相当,这表明这些药物的开发前景广阔,有望在这一药理类别中进一步寻找有效、安全的镇痛药。
INVESTIGATION OF THE ANALGESIC ACTIVITY OF NEW LIGANDS OF THE NMDA RECEPTOR COMPLEX
According to the Russian Society for the Study of Pain, 90% of patients seeking medical help experience pain, with 70% suffering from chronic pain [15, 16]. It should be acknowledged that the capabilities of traditional analgesic methods are limited, and the prescription of opioids is associated with an increase in complications, the development of tolerance, drug dependence, and an increase in the patient's hospital stay costs. Thus, the main directions for improving pain relief include the rational combination of analgesics with different mechanisms of action and the development of new effective and safe medicinal substances with analgesic activity. It is known that the activation of spinal cord NMDA receptors is a key factor in the pathogenesis of acute and chronic pain. Therefore, the use of existing NMDA antagonists in analgesic schemes, as well as the development of new compounds targeting the NMDA receptor complex, is of particular interest. New ligands of the glutamate NMDA receptor complex are derivatives of imidazole-4,5-dicarboxylic acid. The conformational rigidity of the molecules of imidazole-4,5-dicarboxylic acid derivatives allow for increased selectivity of interaction and reduced side effects. The aim of the study was to investigate the analgesic effect of new ligands of the glutamate NMDA receptor complex - derivatives of imidazole-4,5-dicarboxylic acid in mice using the tail-flick test and the formalin test. The tested compounds (IEM-303 and IEM-2044) were administered intraperitoneally at doses of 5, 10, 15, 20 mg/kg. Мetamizole was used as a comparison drug. The experiments demonstrated a significant dose-dependent analgesic effect of the tested compounds in experimental models of acute pain at doses of 5-20 mg/kg. In the groups receiving IEM-2044 and IEM-303, the tail-flick latency increased by 1.4-1.7 times compared to the control group. The analgesic activity of the tested compounds at doses of 10-20 mg/kg was comparable to the analgesic activity of metamizole, indicating the prospect of developing these agents and further searching for effective and safe analgesics among this pharmacological class.